Autopsy report · NCT05665595

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

“Business Reason”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 8 months before it stopped.
• 1,594 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

Melanoma

Interventions

Pembrolizumab/Vibostolimab; Pembrolizumab

Participants

1,594

Sites

205

Countries

Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, India and more

Trials that died the same way

• Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia
  “Business reasons” (94% match in meaning)
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
  “Business/Commercial Reasons” (80% match in meaning)
• Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
  “Financial/Business Reasons” (80% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (78% match in meaning)
• Comparative Bioavailability Study of Metformin HCl 1000 mg Granules vs Glucophage 1000 mg Film-coated Tablet
  “Commercial reasons” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.